eligibility_summary
Eligible: confirmed B-precursor B-ALL or DLBCL/Burkitt lymphoma, or histologically confirmed neuroblastoma or Ewing sarcoma. Key exclusions: solid organ transplant, active cardiovascular disease, liver cirrhosis, >Grade 1 neuropathy, demyelinating CMT, Down syndrome, GVHD or its therapy, HIV, hypersensitivity to study drugs, recent radiotherapy/anticancer or investigational therapy, chronic steroids >10 mg, strong CYP3A4 modulators, recent live vaccine, other active malignancy, active infection, hepatitis B or active C, unresolved major surgery.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase 1/2, single-arm pediatric/young adult study of zilovertamab vedotin (MK-2140, VLS-101) in relapsed/refractory B-ALL, DLBCL/Burkitt lymphoma, neuroblastoma, and Ewing sarcoma. Drug/intervention and mechanism: Zilovertamab vedotin is an antibody–drug conjugate (ADC) immunotherapy/targeted therapy. It consists of a humanized anti-ROR1 monoclonal antibody linked via a cleavable linker to the cytotoxic payload monomethyl auristatin E (MMAE), a microtubule inhibitor. After binding ROR1 on tumor cells, the ADC is internalized and releases MMAE, causing microtubule disruption, mitotic arrest, and apoptosis, the antibody may also inhibit ROR1 signaling. Target cells/pathways: ROR1-expressing malignant B cells (B-ALL, DLBCL/Burkitt) and pediatric solid tumor cells (neuroblastoma, Ewing sarcoma). Pathways affected include ROR1-driven noncanonical Wnt signaling and microtubule dynamics. Administered IV every 3 weeks with dose escalation.